About AudioCure

AudioCure Pharma is an innovative clinical-stage pharmaceutical company focused on developing treatments for audiological and neurological disorders with a high unmet medical need.

Our small molecules have shown Proof-of-Principle in preclinical models for a range of otic disorders including hearing loss, tinnitus and electrode insertion trauma as well as Parkinson’s Disease. The safety and tolerability of AudioCure’s lead compound AC102 has been demonstrated in a first-in-human clinical trial. Currently, a Proof-of-Concept, Phase 2 clinical trial evaluating AC102’s efficacy in patients with Sudden Sensorineural Hearing Loss is underway across Europe.

Join us to make a meaningful impact on the lives of those affected by these disorders and turn incurable hearing loss into a treatable event.

Press releases

29. November 2016

AudioCure Pharma GmbH secures funding of about EUR 9 million for the further development of their lead candidate, AC102, in hearing loss

AudioCure, a pharmaceutical R&D company headquartered in Germany, announces today that it has secured an A-round of about EUR 9 million from MED-EL, HTGF and private investors. MED-EL receives exclusive licensing rights and shares while existing investors increase their shares. AudioCure will use the funding to get its front-runner small molecule AC102 into Phase I clinical trials in auditory disorders including acute hearing loss and acute tinnitus. To date, there are no approved therapeuti
29. May 2012

High-Tech Gründerfonds and Business Angel Invest in AudioCure Pharma GmbH Drug Development

AudioCure Pharma concentrates on the clinical development of drug candidates in neurodegenerative disease indications with a high unmet medical need. The lead candidate is a small molecule compound for the treatment of acute and chronic hearing impairments via local, regenerative therapy of the damaged nerve cells in the inner ear. Seed financing from High-Tech Gründerfonds and business angel Dr. Schumacher will enable AudioCure to develop the lead compound for the medicinal treatment of hea

Info & Contact

Dr. Reimar Schlingensiepen, CEO


Schlegelstr. 9
10115 Berlin

In portfolio

20. Apr 2012



Dr. Christian Kannemeier

Senior Investment Manager